Evaxion to present new phase 2 data for ai-designed personalized cancer vaccine evx-01 at aacr annual meeting

Copenhagen, denmark, march 25, 2025 - evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, will present new data for its lead asset evx-01 at a poster session at the american association for cancer research (aacr) annual meeting taking place in chicago april 25-30, 2025. designed with evaxion's ai-immunology™ platform, evx-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
EVAX Ratings Summary
Quant
EVAX Quant Ranking
Sector
Industry
Quant Rating
Quant Score